^aBased on the results of the Ulcerative Colitis Narrative global patient and physician surveys, which aimed to identify the impact of UC and comparing and contrasting perceptions of UC burden and management approaches. Surveys of patients with UC (self-reported diagnosis; N=2100) and physicians (N=1254) were completed across 10 countries between August 2017 and February 2018²; ^bMissing a mean of 7.3 working days (standard deviation, 16.6) because of UC symptoms²; ^cPatients were considered in remission if they showed a partial Mayo score ≤2, with no subscore >1³; ^dBased on results from a cross-sectional study conducted from March 2019 to March 2020 at the U.O. of Pathophysiology of the Digestive System of the University Magna Graecia of Catanzaro (Catanzaro, Italy), in which patients with inflammatory bowel disease (IBD) (202 patients [29% with Crohn’s disease (CD); 71% with UC]) in clinical remission were enrolled in order to assess their perceptions and unmet needs related to their health-related quality of life.³